UBS Group’s SAB Biotherapeutics Warrant SABSW Stock Holding History
Bought
Maintained
Sold
Other funds holding SABSW
UBS Group's SABSW Position: Q3 2026 in Review
UBS Group reduced its SAB Biotherapeutics Warrant (SABSW) stake by 4.6% in Q3 2026, selling an estimated $5 and leaving 6,267 shares worth $88. The position accounts for ﹤0.01% of the portfolio, ranked #10876.
UBS Group first reported a position in SABSW in Q1 2021 and has held it in 14 quarters since. The position peaked at $5K in Q4 2021. 10 funds tracked by Wall St. Rank hold SABSW as of Q3 2026.
- UBS Group held 6,267 shares of SAB Biotherapeutics Warrant worth $88 as of Q3 2026.
- UBS Group sold 300 SAB Biotherapeutics Warrant shares in Q3 2026, an estimated $5.
- SAB Biotherapeutics Warrant made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10876 holding.
- UBS Group first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and has held it in 14 quarters since.
- UBS Group's SAB Biotherapeutics Warrant position peaked at $5K in Q4 2021.
- 10 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.